A
A. Artal-Cortes
Publications - 10
Citations - 2304
A. Artal-Cortes is an academic researcher. The author has contributed to research in topics: Atezolizumab & Docetaxel. The author has an hindex of 6, co-authored 8 publications receiving 1880 citations.
Papers
More filters
Journal ArticleDOI
Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial
Louis Fehrenbacher,Alexander I. Spira,Marcus Ballinger,Marcin Kowanetz,Johan Vansteenkiste,Julien Mazieres,Keunchil Park,David J. Smith,A. Artal-Cortes,Conrad R. Lewanski,Fadi Braiteh,Daniel Waterkamp,Pei He,Wei Zou,Daniel S. Chen,Jing Yi,Alan Sandler,Achim Rittmeyer +17 more
TL;DR: This open-label, phase 2 randomised controlled trial assessed efficacy and safety of atezolizumab versus docetaxel in previously treated NSCLC, analysed by PD-L1 expression levels on tumours and tumour-infiltrating immune cells and in the intention-to-treat population.
Journal ArticleDOI
14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)
Johan Vansteenkiste,Louis Fehrenbacher,Alexander I. Spira,Julien Mazieres,K. Park,David J. Smith,A. Artal-Cortes,Conrad R. Lewanski,Fadi Braiteh,Jing Yi,Pei He,Marcin Kowanetz,Daniel Waterkamp,Marcus Ballinger,D.S. Chen,Alan Sandler,Achim Rittmeyer +16 more
Journal ArticleDOI
Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).
David Smith,Johan Vansteenkiste,Louis Fehrenbacher,Keunchil Park,Julien Mazieres,Achim Rittmeyer,A. Artal-Cortes,Conrad R. Lewanski,Fadi Braiteh,Jing Yi,Pei He,Wei Zou,Marcin Kowanetz,Daniel Waterkamp,Marcus Ballinger,Daniel S. Chen,Alan Sandler,Alexander I. Spira +17 more
TL;DR: Atezolizumab (atezo, MPDL3280A), a humanized engineered mAb, is the first anti-PD-L1 agent to show improved OS vs docetaxel (doc) in NSCLC.
Journal ArticleDOI
Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.
Julien Mazieres,Louis Fehrenbacher,Achim Rittmeyer,Alexander I. Spira,Keunchil Park,David Smith,A. Artal-Cortes,Conrad R. Lewanski,Fadi Braiteh,Jing Yi,Pei He,Marcin Kowanetz,Daniel Waterkamp,Marcus Ballinger,Daniel S. Chen,Alan Sandler,Johan Vansteenkiste +16 more
TL;DR: This data indicates that tumor immune infiltration or delayed response to RECIST-based immunotherapy can induce unconventional response patterns due to tumor immune infiltrate or delay in response to chemotherapy, and this data points to the need for further research.
Journal ArticleDOI
136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR)
Julien Mazieres,K. Park,Conrad R. Lewanski,Shirish M. Gadgeel,Louis Fehrenbacher,Achim Rittmeyer,J-Y. Han,A. Artal-Cortes,Fadi Braiteh,Johan Vansteenkiste +9 more